An investigational HER2-targeting antibody-drug conjugate comprising a humanized anti-HER2 monoclonal antibody linked via an enzyme-cleavable linker to a topoisomerase I inhibitor payload; after HER2 binding and internalization, the linker is cleaved intracellularly to release the cytotoxic payload, causing DNA damage and cell death.
A humanized anti-HER2 monoclonal antibody linked via an intracellularly cleavable linker to a topoisomerase I inhibitor. After HER2 binding and internalization, the linker is cleaved to release the payload, which inhibits topoisomerase I, induces DNA damage, and leads to tumor cell death.
YES
DIRECT
Anti-HER2 ADC binds HER2, is internalized, linker is cleaved intracellularly to release a topoisomerase I inhibitor that causes DNA damage and kills the target cell.
An investigational HER2-targeting antibody-drug conjugate comprising a humanized anti-HER2 monoclonal antibody linked via an enzyme-cleavable linker to a topoisomerase I inhibitor payload; after HER2 binding and internalization, the linker is cleaved intracellularly to release the cytotoxic payload, causing DNA damage and cell death.
A humanized anti-HER2 monoclonal antibody linked via an intracellularly cleavable linker to a topoisomerase I inhibitor. After HER2 binding and internalization, the linker is cleaved to release the payload, which inhibits topoisomerase I, induces DNA damage, and leads to tumor cell death.
NO
INDIRECT
TQB2102 is an anti-HER2 ADC; it binds HER2, is internalized, and releases a topoisomerase I inhibitor that causes DNA damage and cell death. DNA topoisomerase I is the intracellular payload target, not the antigen used to direct killing.
HER2-targeted antibody–drug conjugate linking trastuzumab to a topoisomerase I inhibitor (DXd); binds HER2, mediates ADCC, internalizes and releases DXd to induce DNA damage (bystander effect).
HER2-targeted antibody–drug conjugate: trastuzumab binds HER2, inhibits signaling and mediates ADCC; the complex is internalized and releases the topoisomerase I inhibitor DXd, causing DNA damage and cell death with a bystander effect.
YES
DIRECT
The ADC binds HER2, is internalized, and releases the DXd topoisomerase I inhibitor, causing DNA damage and apoptosis; trastuzumab Fc can also mediate ADCC, with a membrane‑permeable payload enabling a bystander effect.
An intravenous bispecific T-cell engager (BiTE) antibody (AMG 757; IMDELLTRA) that binds DLL3 on SCLC tumor cells and CD3 on T cells, creating an immune synapse to activate TCR/CD3 signaling and redirect T-cell cytotoxicity against DLL3-expressing cells.
Bispecific T-cell engager antibody that binds DLL3 on tumor cells and CD3 on T cells, creating an immune synapse that activates TCR/CD3 signaling and redirects T-cell cytotoxicity to kill DLL3-expressing cells (e.g., SCLC).
NO
INDIRECT
Tarlatamab binds CD3 on T cells to activate them and bridge to DLL3+ tumor cells; the activated T cells kill DLL3-expressing tumor cells (perforin/granzyme), not the CD3+ cells.
HER2-targeted antibody–drug conjugate linking trastuzumab to a topoisomerase I inhibitor (DXd); binds HER2, mediates ADCC, internalizes and releases DXd to induce DNA damage (bystander effect).
HER2-targeted antibody–drug conjugate: trastuzumab binds HER2, inhibits signaling and mediates ADCC; the complex is internalized and releases the topoisomerase I inhibitor DXd, causing DNA damage and cell death with a bystander effect.
NO
INDIRECT
T-DXd targets HER2, is internalized, and releases the DXd payload that inhibits topoisomerase I to cause DNA damage and cell death; topoisomerase I expression alone does not make cells targets (bystander killing may occur).